Exchange: NASDAQ
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
4,414,000 | 4,281,000 | 4,459,000 | 4,037,000 | 3,999,000 |
Cost of Goods Sold (COGS) incl. D&A |
925,000 | 779,000 | 755,000 | 753,000 | 729,000 |
COGS excluding D&A |
579,000 | 492,000 | 486,000 | 494,000 | 469,000 |
Depreciation & Amortization Expense |
346,000 | 287,000 | 269,000 | 259,000 | 260,000 |
Gross Income |
3,489,000 | 3,502,000 | 3,704,000 | 3,284,000 | 3,270,000 |
SG&A Expense |
2,308,000 | 2,007,000 | 2,054,000 | 1,812,000 | 2,106,000 |
Research & Development |
938,000 | 880,000 | 826,000 | 736,000 | 851,000 |
Other SG&A |
1,370,000 | 1,127,000 | 1,228,000 | 1,076,000 | 1,255,000 |
Other Operating Expense |
32,000 | 57,000 | 79,000 | 6,000 | -7,000 |
Unusual Expense |
48,000 | -46,000 | -20,000 | -32,000 | 50,000 |
Non Operating Income/Expense |
0 | 50,000 | 121,000 | 121,000 | 77,000 |
Equity in Affiliates (Pretax) |
NA | 0 | 0 | 0 | 0 |
Interest Expense |
291,000 | 271,000 | 255,000 | 253,000 | 194,000 |
Gross Interest Expense |
317,000 | 271,000 | 255,000 | 253,000 | 194,000 |
Pretax Income |
923,000 | 1,263,000 | 1,457,000 | 1,366,000 | 1,004,000 |
Income Tax |
135,000 | 156,000 | 191,000 | 182,000 | 117,000 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 47,000 |
Consolidated Net Income |
788,000 | 1,107,000 | 1,266,000 | 1,184,000 | 934,000 |
Minority Interest Expense |
0 | 0 | 0 | 0 | 0 |
Net Income |
788,000 | 1,107,000 | 1,266,000 | 1,184,000 | 934,000 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Net Income After Extraordinaries |
788,000 | 1,107,000 | 1,266,000 | 1,184,000 | 934,000 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
788,000 | 1,107,000 | 1,266,000 | 1,184,000 | 934,000 |
Operational EPS |
1.04 | 1.37 | 1.59 | 1.45 | 1.06 |
EPS (basic) |
1.03 | 1.44 | 1.63 | 1.50 | 1.03 |
EBITDA |
1,495,000 | 1,725,000 | 1,840,000 | 1,725,000 | 1,431,000 |
Depreciation & Amortization Expense |
346,000 | 287,000 | 269,000 | 259,000 | 260,000 |
Common Shares Outstanding |
787,000 | 783,000 | 785,000 | 800,000 | 912,000 |
Basic Shares Outstanding |
775,000 | 771,000 | 776,000 | 791,000 | 905,000 |
Diluted Shares Outstanding |
787,000 | 783,000 | 785,000 | 800,000 | 912,000 |
Diluted EPS after Extraordinary Items |
1.00 | 1.41 | 1.61 | 1.48 | 1.02 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
1.02 | 1.44 | 1.63 | 1.50 | 1.02 |
*Figures in thousands of U.S. Dollars except shares outstanding.
